Journal Watch · Journal for ImmunoTherapy of Cancer · 2026

Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis.

The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

Igase M, Hagimori K, Inanaga S et al.Journal for ImmunoTherapy of Cancer4 min readPharma relevance 85/100

DOI: 10.1136/jitc-2025-013623PMID: 41571458Study type: cohort / observational clinical study

TL;DR

The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

Key findings

  • Increased baseline white blood cell, neutrophil count, and C reactive protein levels were significantly associated with poor response, shorter progression-free survival, and reduced overall survival (OS).
  • MSI-high tumors were associated with significantly prolonged OS compared with MSI-low/microsatellite stable tumors.
  • Transcriptome analysis revealed differentially expressed genes and enriched immune-related pathways in responders, though limited by sample size.<h4>Conclusion</h4>ca-4F12-E6 exhibited durable antitumor activity with manageable safety profile in dogs with OMM.
  • Baseline systemic inflammatory markers and MSI status may serve as predictive biomarkers for clinical outcomes.
  • The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

Numbers at a glance (from the abstract)

14.7%16.7%40.0%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Treatment response was assessed using cRECIST V.1.0. Biomarker analyses included peripheral blood parameters, cytokine/chemokines, peripheral lymphocyte subsets, microsatellite instability (MSI), immunohistochemistry for immune cell and mismatch repair protein markers, and RNA sequencing of the tumor tissue. Associations with clinical outcomes were determined by logistic regression and Cox proportional hazards models.<h4>Results</h4>The overall response rate was 14.7%, with a best overall response rate of 16.7%. Treatment-related adverse events occurred in 40.0% of the dogs, which were primarily grade 1-3.

Full abstract (original)

Background: <h4>Background</h4>Canine oral malignant melanoma (OMM) is a highly aggressive tumor, with several available treatment options, though few achieve durable response or complete remission. Because of its biological similarity to human mucosal melanoma, canine OMM represents a valuable spontaneous model for translational immunotherapy studies. Anti-programmed cell death protein 1 (PD-1) antibody therapy has shown promise in canine OMM; however, predictive biomarkers for treatment response and survival have not been identified.<h4>Methods</h4>We conducted a multicenter, prospective, investigator-initiated clinical trial to evaluate the safety and efficacy of a caninized anti-canine PD-1 monoclonal antibody (ca-4F12-E6) in 150 dogs with advanced OMM. The dogs were administered 3 mg/kg ca-4F12-E6 intravenously every 2 weeks.

What they did: Treatment response was assessed using cRECIST V.1.0. Biomarker analyses included peripheral blood parameters, cytokine/chemokines, peripheral lymphocyte subsets, microsatellite instability (MSI), immunohistochemistry for immune cell and mismatch repair protein markers, and RNA sequencing of the tumor tissue. Associations with clinical outcomes were determined by logistic regression and Cox proportional hazards models.<h4>Results</h4>The overall response rate was 14.7%, with a best overall response rate of 16.7%. Treatment-related adverse events occurred in 40.0% of the dogs, which were primarily grade 1-3.

Results & conclusions: Increased baseline white blood cell, neutrophil count, and C reactive protein levels were significantly associated with poor response, shorter progression-free survival, and reduced overall survival (OS). MSI-high tumors were associated with significantly prolonged OS compared with MSI-low/microsatellite stable tumors. Transcriptome analysis revealed differentially expressed genes and enriched immune-related pathways in responders, though limited by sample size.<h4>Conclusion</h4>ca-4F12-E6 exhibited durable antitumor activity with manageable safety profile in dogs with OMM. Baseline systemic inflammatory markers and MSI status may serve as predictive biomarkers for clinical outcomes. The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

Abstract © the authors / Journal for ImmunoTherapy of Cancer (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1136/jitc-2025-013623 · PubMed 41571458.

Why it matters for pharma & biotech

  • Directly relevant to teams in antibody / ADC therapeutics, targeted oncology / immuno-oncology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: antibody / ADC therapeutics · targeted oncology / immuno-oncology

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Journal for ImmunoTherapy of Cancer study find?

The results support the use of canine OMM as a comparative model for human immuno-oncology and biomarker discovery.

What type of study is this?

It is a cohort / observational clinical study, published in Journal for ImmunoTherapy of Cancer in 2026. Treatment response was assessed using cRECIST V.1.0.

Where can I read the original paper?

The original is at the publisher via DOI 10.1136/jitc-2025-013623. PubMed ID: 41571458. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Igase M, Hagimori K, Inanaga S et al.. Caninized PD-1 monoclonal antibody in oral malignant melanoma: efficacy and exploratory biomarker analysis.. Journal for ImmunoTherapy of Cancer (2026). DOI: 10.1136/jitc-2025-013623.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/caninized-pd-1-monoclonal-antibody-in-oral-malignant-melanoma-efficacy-a-013623/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides